Literature DB >> 29464574

Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.

Anne Luise Haulund Vollesen1, Faisal Mohammad Amin1, Messoud Ashina2.   

Abstract

Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine pathophysiology and data implicating PAC1 receptor as a future drug target in migraine. Much remains to be fully elucidated about migraine pathophysiology, but recent attention has focused on signaling molecule PACAP38, a vasodilator able to induce migraine attacks in patients who experience migraine without aura. PACAP38, with marked and sustained effect, dilates extracerebral arteries but not the middle cerebral artery. The selective affinity of PACAP38 to the PAC1 receptor makes this receptor a highly interesting and potential novel target for migraine treatment. Efficacy of antagonism of this receptor should be investigated in randomized clinical trials.

Entities:  

Keywords:  Human provocation models; Migraine; PAC1 receptor; PACAP38; Primary headaches; Vasoactive intestinal polypeptide

Mesh：

Substances：

Year:  2018        PMID： 29464574      PMCID： PMC5935633          DOI： 10.1007/s13311-017-0596-x

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


  79 in total

1.  Cellular distribution of the splice variants of the receptor for pituitary adenylate cyclase-activating polypeptide (PAC(1)-R) in the rat brain by in situ RT-PCR.

Authors:  C J Zhou; S Kikuyama; M Shibanuma; T Hirabayashi; S Nakajo; A Arimura; S Shioda
Journal:  Brain Res Mol Brain Res       Date:  2000-01-10

2.  Interictal plasma pituitary adenylate cyclase-activating polypeptide levels are decreased in migraineurs but remain unchanged in patients with tension-type headache.

Authors:  Xun Han; Zhao Dong; Lei Hou; Dongjun Wan; Min Chen; Wenjing Tang; Shengyuan Yu
Journal:  Clin Chim Acta       Date:  2015-08-19       Impact factor: 3.786

3.  PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.

Authors:  Inger Jansen-Olesen; Michael Baun; Dipak V Amrutkar; Roshni Ramachandran; Daniel V Christophersen; Jes Olesen
Journal:  Neuropeptides       Date:  2014-01-25       Impact factor: 3.286

4.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.

Authors:  T B Usdin; T I Bonner; E Mezey
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

5.  Pituitary adenylate cyclase-activating polypeptide (PACAP)-like immunoreactive neuronal elements in rat hypothalamus and median eminence with special reference to morphological background of its effect on anterior pituitary--light and electron microscopic immunocytochemistry.

Authors:  Y Tamada; M Tanaka; Y Ichitani; H Okamura; N Yanaihara; Y Ibata
Journal:  Neurosci Lett       Date:  1994-10-24       Impact factor: 3.046

6.  Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients.

Authors:  Bernadett Tuka; Zsuzsanna Helyes; Adrienn Markovics; Teréz Bagoly; János Szolcsányi; Nikoletta Szabó; Eszter Tóth; Zsigmond Tamás Kincses; László Vécsei; János Tajti
Journal:  Cephalalgia       Date:  2013-04-18       Impact factor: 6.292

7.  Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study.

Authors:  H Hashimoto; H Nogi; K Mori; H Ohishi; R Shigemoto; K Yamamoto; T Matsuda; N Mizuno; S Nagata; A Baba
Journal:  J Comp Neurol       Date:  1996-08-05       Impact factor: 3.215

8.  Pituitary adenylate cyclase activating peptide (PACAP) mRNA in the rat neocortex.

Authors:  J D Mikkelsen; J Hannibal; P J Larsen; J Fahrenkrug
Journal:  Neurosci Lett       Date:  1994-04-25       Impact factor: 3.046

9.  Change in brain network connectivity during PACAP38-induced migraine attacks: A resting-state functional MRI study.

Authors:  Faisal Mohammad Amin; Anders Hougaard; Stefano Magon; Mohammad Sohail Asghar; Nur Nabil Ahmad; Egill Rostrup; Till Sprenger; Messoud Ashina
Journal:  Neurology       Date:  2015-12-16       Impact factor: 9.910

10.  Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.

Authors:  W A Banks; A J Kastin; G Komaki; A Arimura
Journal:  J Pharmacol Exp Ther       Date:  1993-11       Impact factor: 4.030
View more
  12 in total

Review 1.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

2.  Migraine Therapy: Current Approaches and New Horizons.

Authors:  Peter J Goadsby; Philip R Holland
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

3.  PACAP and Other Neuropeptide Targets Link Chronic Migraine and Opioid-induced Hyperalgesia in Mouse Models.

Authors:  Krishna D. B. Anapindi; Ning Yang; Elena V Romanova; Stanislav S Rubakhin; Alycia Tipton; Isaac Dripps; Zoie Sheets; Jonathan V Sweedler; Amynah A Pradhan
Journal:  Mol Cell Proteomics       Date:  2019-10-24       Impact factor: 5.911

Review 4.  Migraine and the trigeminovascular system-40 years and counting.

Authors:  Messoud Ashina; Jakob Møller Hansen; Thien Phu Do; Agustin Melo-Carrillo; Rami Burstein; Michael A Moskowitz
Journal:  Lancet Neurol       Date:  2019-05-31       Impact factor: 44.182

5.  New discoveries in migraine mechanisms and therapeutic targets.

Authors:  Greg Dussor
Journal:  Curr Opin Physiol       Date:  2019-10-18

Review 6.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

Review 7.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

8.  Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: Relevant to migraine.

Authors:  Qing Zhang; Xun Han; Hangfei Wu; Mingjie Zhang; Guanqun Hu; Zhao Dong; Shengyuan Yu
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

9.  Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?

Authors:  Messoud Ashina; Paolo Martelletti
Journal:  J Headache Pain       Date:  2018-05-08       Impact factor: 7.277

10.  VPAC1 receptors play a dominant role in PACAP-induced vasorelaxation in female mice.

Authors:  Ivan Ivic; Marta Balasko; Balazs D Fulop; Hitoshi Hashimoto; Gabor Toth; Andrea Tamas; Tamas Juhasz; Akos Koller; Dora Reglodi; Margit Solymár
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.